2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读

Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Non-small cell lung cancer (NSCLC) is the main pathological subtype of lung cancer. On April 13, 2023, the National Comprehensive Cancer Network (NCCN) released the third edition of the 2023 NCCN Oncology Clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHU, Lingling, WANG, Ting, WU, Juan, ZHAI, Xiaoqian, WU, Qiang, DENG, Hanyu, QIN, Changlong, TIAN, Long, ZHOU, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Guideline Interpretation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365961/
https://www.ncbi.nlm.nih.gov/pubmed/37488078
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.18
_version_ 1785077067013947392
author ZHU, Lingling
WANG, Ting
WU, Juan
ZHAI, Xiaoqian
WU, Qiang
DENG, Hanyu
QIN, Changlong
TIAN, Long
ZHOU, Qinghua
author_facet ZHU, Lingling
WANG, Ting
WU, Juan
ZHAI, Xiaoqian
WU, Qiang
DENG, Hanyu
QIN, Changlong
TIAN, Long
ZHOU, Qinghua
author_sort ZHU, Lingling
collection PubMed
description Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Non-small cell lung cancer (NSCLC) is the main pathological subtype of lung cancer. On April 13, 2023, the National Comprehensive Cancer Network (NCCN) released the third edition of the 2023 NCCN Oncology Clinical Practice Guidelines: Non-small Cell Lung Cancer, which reflects the latest advances in international lung cancer research. This article will interpret the main updated contents of the new edition of the guidelines, and compare it with the third edition of the NCCN guidelines in 2022, so as to provide references about the diagnosis and treatment of NSCLC for clinical medical personnel in China.
format Online
Article
Text
id pubmed-10365961
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial board of Chinese Journal of Lung Cancer
record_format MEDLINE/PubMed
spelling pubmed-103659612023-07-26 2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读 ZHU, Lingling WANG, Ting WU, Juan ZHAI, Xiaoqian WU, Qiang DENG, Hanyu QIN, Changlong TIAN, Long ZHOU, Qinghua Zhongguo Fei Ai Za Zhi Guideline Interpretation Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Non-small cell lung cancer (NSCLC) is the main pathological subtype of lung cancer. On April 13, 2023, the National Comprehensive Cancer Network (NCCN) released the third edition of the 2023 NCCN Oncology Clinical Practice Guidelines: Non-small Cell Lung Cancer, which reflects the latest advances in international lung cancer research. This article will interpret the main updated contents of the new edition of the guidelines, and compare it with the third edition of the NCCN guidelines in 2022, so as to provide references about the diagnosis and treatment of NSCLC for clinical medical personnel in China. Editorial board of Chinese Journal of Lung Cancer 2023-06-20 /pmc/articles/PMC10365961/ /pubmed/37488078 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.18 Text en 版权所有 © 2023《中国肺癌杂志》编辑部 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle Guideline Interpretation
ZHU, Lingling
WANG, Ting
WU, Juan
ZHAI, Xiaoqian
WU, Qiang
DENG, Hanyu
QIN, Changlong
TIAN, Long
ZHOU, Qinghua
2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读
title 2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读
title_full 2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读
title_fullStr 2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读
title_full_unstemmed 2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读
title_short 2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读
title_sort 2023年第3版《nccn肿瘤临床实践指南：非小细胞肺癌》更新解读
topic Guideline Interpretation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365961/
https://www.ncbi.nlm.nih.gov/pubmed/37488078
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.18
work_keys_str_mv AT zhulingling 2023niándì3bǎnnccnzhǒngliúlínchuángshíjiànzhǐnánfēixiǎoxìbāofèiáigèngxīnjiědú
AT wangting 2023niándì3bǎnnccnzhǒngliúlínchuángshíjiànzhǐnánfēixiǎoxìbāofèiáigèngxīnjiědú
AT wujuan 2023niándì3bǎnnccnzhǒngliúlínchuángshíjiànzhǐnánfēixiǎoxìbāofèiáigèngxīnjiědú
AT zhaixiaoqian 2023niándì3bǎnnccnzhǒngliúlínchuángshíjiànzhǐnánfēixiǎoxìbāofèiáigèngxīnjiědú
AT wuqiang 2023niándì3bǎnnccnzhǒngliúlínchuángshíjiànzhǐnánfēixiǎoxìbāofèiáigèngxīnjiědú
AT denghanyu 2023niándì3bǎnnccnzhǒngliúlínchuángshíjiànzhǐnánfēixiǎoxìbāofèiáigèngxīnjiědú
AT qinchanglong 2023niándì3bǎnnccnzhǒngliúlínchuángshíjiànzhǐnánfēixiǎoxìbāofèiáigèngxīnjiědú
AT tianlong 2023niándì3bǎnnccnzhǒngliúlínchuángshíjiànzhǐnánfēixiǎoxìbāofèiáigèngxīnjiědú
AT zhouqinghua 2023niándì3bǎnnccnzhǒngliúlínchuángshíjiànzhǐnánfēixiǎoxìbāofèiáigèngxīnjiědú

Ejemplares similares